HCA Healthcare stock holds above $400 as Q2 2026 growth supports outlook

HCA Healthcare Inc. (US40412C1018) stock is trading just above $400 per share as of the close on August 17, 2026, supported by strong second quarter 2026 growth in revenue and earnings that has helped underpin investor confidence in the hospital group.

Q2 2026 results show revenue and earnings growth

According to a market overview that summarizes quarterly figures, HCA Healthcare reported second quarter fiscal 2026 revenue of $20.23 billion, with earnings of $1.7 billion for the period ended in Q2 2026, highlighting a profitable expansion of its hospital operations. The same overview indicates that the company delivered GAAP earnings per share of $7.59 in Q2 2026 versus an estimated $7.5, meaning it exceeded consensus by $0.09 per share and underscoring a modest but clear earnings beat for the quarter. A separate analysis of hospital operators notes that in the second quarter of 2026 HCA Healthcare achieved same-facility equivalent admissions growth of 2.7 percent, while revenue per equivalent admission rose 6.4 percent in the same period, pointing to a combination of increased patient volumes and improved pricing and mix.

The day after HCA Healthcare released its quarterly results, an earnings commentary reports that the shares moved from $376 to $383, reflecting a positive initial reaction to the numbers even though the article also cautions that investors should look closely at the fine print of the report. For hospital investors, the combination of higher admissions and a mid-single-digit increase in revenue per admission is important because it suggests that demand for acute care services remains healthy and that HCA Healthcare has been able to sustain favorable reimbursement trends and manage its payer mix effectively in Q2 2026.

Valuation, consensus view and recent trading range

Real-time quote data for HCA Healthcare on a US exchange shows that the shares closed at $404.98 on August 17, 2026, with a modest gain of $0.30, or 0.07 percent, for that completed regular trading session. In the pre-market session that followed, the same quote source lists the stock at $400.35, down $4.63 or 1.14 percent, highlighting how the price has recently traded in a narrow band slightly above the $400 level as investors digest the Q2 2026 report and sector news. A dedicated stock-analysis page that tracks the latest closing data states that HCA Healthcare ended trading on August 17, 2026 at $405.575, up 0.22 percent on the day, which places the shares effectively flat to slightly higher around that $405 mark over the latest completed session and indicates that the stock is holding its ground rather than staging a sharp move in either direction.

An institutional-investor filing snapshot notes that HCA Healthcare shares opened at $405.53 in the latest session referenced in that filing, a level consistent with the broader $400 to $410 recent trading range, while the same set of filings cites an average analyst price target of $465.59 and an average rating categorized as Moderate Buy. Taken together, this implies that the sell-side still sees upside of roughly $60 per share or a mid-teens percentage from the latest $404 to $405 trading area, even after the strong run the stock has already enjoyed over the past year. Another research-focused article that compares healthcare stocks points out that HCA Healthcare’s stock price of $404.53 corresponds to a valuation of 13.2 times forward earnings, suggesting that the market is pricing the hospital operator at a mid-teens multiple that reflects its stable cash flows but does not fully mirror the more aggressive valuation levels sometimes seen in higher-growth health technology names.

Sector comparison and demand backdrop

A sector comparison piece that looks at several large US hospital operators highlights HCA Healthcare’s recent performance in the context of peers such as Tenet Healthcare. The article notes that while Tenet reported a 22.3 percent jump in adjusted hospital EBITDA and margin expansion in its latest quarter, HCA Healthcare also delivered solid same-facility equivalent admissions growth of 2.7 percent and a 6.4 percent increase in revenue per equivalent admission in the second quarter of 2026. For investors, the key takeaway from this comparison is that demand for hospital services remains firm across large networks, with HCA Healthcare participating in the broader trend of rising patient volumes and improving revenue per visit.

Importantly, the combination of admissions growth and revenue-per-admission growth at HCA Healthcare in Q2 2026 provides a quantified picture of operating leverage. If revenue per equivalent admission increases faster than patient volumes, fixed costs are spread over a larger revenue base, enhancing margins. While the sector article focuses mainly on Tenet’s margin expansion, HCA Healthcare’s metrics suggest that it too is benefiting from favorable operating dynamics, which, together with the $1.7 billion in quarterly earnings and the earnings-per-share beat against the $7.5 estimate, helps explain why the shares have stabilized in the low $400s rather than pulling back sharply after results.

HCA Healthcare’s core hospital network and services

HCA Healthcare’s business is built around a large network of hospitals and related facilities in the United States, with operations that include acute care hospitals, outpatient surgery centers, emergency rooms, and physician practices. The company focuses on providing inpatient and outpatient medical services across multiple specialties, including cardiology, oncology, orthopedics, and women’s and children’s health, among others. Within this network, same-facility equivalent admissions growth of 2.7 percent in Q2 2026 indicates that more patients are being treated at existing locations, while the 6.4 percent increase in revenue per equivalent admission suggests that higher acuity cases, improved reimbursement rates, or greater use of ancillary services are contributing to overall revenue growth.

For US retail investors, one representative aspect of HCA Healthcare’s operations is its emphasis on managing capacity and staffing to align with demand. When patient volumes increase, the company must balance the need to staff up in clinical and support roles with the goal of maintaining margin discipline. The recent Q2 2026 figures show that HCA Healthcare has navigated this challenge successfully so far in the current fiscal year, generating $20.23 billion in quarterly revenue and $1.7 billion in earnings even as it handles rising admissions. Moreover, the modest earnings-per-share beat against consensus expectations indicates that management executed slightly better than the market anticipated, which can help maintain credibility with analysts and investors as the company moves toward its next earnings date.

Current trading level and investor perspective

As of the completed regular trading session on August 17, 2026, HCA Healthcare stock closed at $404.98 on the New York Stock Exchange, with additional quote data from another market source showing a near-identical latest closing level of $405.575 and a pre-market indication of $400.35. This places the shares only modestly below the average analyst price target of $465.59 identified in recent institutional-investor and consensus summaries, implying potential upside on the order of 15 percent if the company continues to execute on its growth strategy and the broader hospital sector remains supported by demographic trends and stable reimbursement frameworks.

For investors evaluating HCA Healthcare today, the key numbers are the Q2 2026 revenue of $20.23 billion, the $1.7 billion in quarterly earnings, the earnings-per-share of $7.59 that beat the $7.5 estimate, and the operating metrics showing 2.7 percent same-facility equivalent admissions growth combined with 6.4 percent growth in revenue per equivalent admission. These figures, together with the current share price just above $400 and the consensus target at $465.59, frame a picture of a hospital operator that is generating robust cash flow from its core business while trading at a mid-teens forward earnings multiple. As of the latest completed session on August 17, 2026, the market appears to be recognizing this performance by keeping HCA Healthcare stock in a relatively tight trading range rather than producing outsized volatility.

Read more

HCA Healthcare detailed quote and earnings overview

Representative service: inpatient acute care

One representative service within HCA Healthcare’s portfolio that matters to both patients and investors is inpatient acute care, which encompasses hospital stays for serious medical conditions requiring intensive treatment and monitoring. Revenue and margin trends in this area are closely linked to the broader operating metrics highlighted in the Q2 2026 figures, including equivalent admissions and revenue per admission. When acute care admissions grow and the company is able to manage reimbursement rates and length of stay efficiently, the resulting revenue can contribute significantly to the $20.23 billion generated in the quarter and help sustain the $1.7 billion in earnings reported for Q2 2026.

HCA Healthcare stock price and as-of data

HCA Healthcare stock trades on the New York Stock Exchange under the ticker HCA, with the most recent completed regular session showing a closing price of $404.98 as of August 17, 2026, 4:00 p.m. ET, according to a detailed quote and earnings overview. Another market-data page that tracks the stock’s latest movement lists a closing level of $405.575 as of August 17, 2026, 4:00 p.m. ET, with a daily change of 0.22 percent, reinforcing that the shares are holding slightly above the $400 mark at the latest close.

Fact box

Company: HCA Healthcare Inc.
ISIN: US40412C1018
Ticker: HCA
Exchange: NYSE
Price (as of August 17, 2026, 4:00 p.m. ET): $404.98 USD
Market cap: $87.68 billion (as of August 17, 2026)
Sector / Industry: Health care / Hospitals